Core Insights - Avermectins are among the most widely used drugs globally, with a market size of $1.371 billion in 2024. The demand for new types of avermectins, such as Ivermectin and Doramectin, is rapidly increasing, with market sizes projected at $3.33 billion and $134 million respectively in 2024 [2][3]. - China's biomanufacturing level for avermectins, particularly for new generics like Ivermectin and Doramectin, has been lagging behind international original research enterprises [2]. - The Microbial Research Institute has successfully enhanced the biomanufacturing yield of avermectins to 9.3 g/L, establishing a significant technological advantage in this field [2]. Group 1 - The Baiweimectin component, developed by a collaborative team, exhibits superior nematicidal activity and has achieved a fermentation yield of 8.4 g/L [3][5]. - A universal reprogramming engineering strategy was developed, which includes a dynamic control system for Streptomyces species, facilitating the efficient production of Baiweimectin [3]. - The technology developed will provide core support for the efficient biomanufacturing of Streptomyces-derived drugs [3]. Group 2 - The economic loss caused by nematode diseases in China reaches up to 80 billion yuan annually, highlighting the importance of Baiweimectin as a biopesticide with independent intellectual property rights [5]. - Baiweimectin is currently undergoing simultaneous pesticide registration applications both domestically and internationally [5]. Group 3 - The fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will focus on AI in biomanufacturing, green chemicals, new materials, future food, and agriculture [7]. - The conference will feature various activities, including a youth forum and a closed-door seminar on the innovation development blue book for AI-enabled biomanufacturing [7].